Boundless Bio, Inc.
BOLD
$1.07
-$0.01-1.20%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -3.26% | 4.02% | 38.60% | 46.78% | 39.84% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -19.06% | -12.02% | 2.71% | 32.49% | 25.16% |
| Operating Income | 19.06% | 12.02% | -2.71% | -32.49% | -25.16% |
| Income Before Tax | 15.93% | 7.66% | -2.13% | -35.44% | -25.32% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 15.93% | 7.66% | -2.13% | -35.44% | -25.32% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 15.93% | 7.66% | -2.13% | -35.44% | -25.32% |
| EBIT | 19.06% | 12.02% | -2.71% | -32.49% | -25.16% |
| EBITDA | 19.59% | 12.45% | -2.43% | -32.72% | -25.38% |
| EPS Basic | 16.42% | 9.03% | 94.24% | 92.45% | 93.07% |
| Normalized Basic EPS | 16.43% | 9.05% | 94.24% | 92.45% | 93.07% |
| EPS Diluted | 16.42% | 9.03% | 94.24% | 92.45% | 93.07% |
| Normalized Diluted EPS | 16.43% | 9.05% | 94.24% | 92.45% | 93.07% |
| Average Basic Shares Outstanding | 0.59% | 1.51% | 1,672.66% | 1,692.76% | 1,709.27% |
| Average Diluted Shares Outstanding | 0.59% | 1.51% | 1,672.66% | 1,692.76% | 1,709.27% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |